Neoadjuvant therapy approaches are currently being explored in clinical trials. For example, an open-label phase III study is exploring sequential neoadjuvant chemoradiotherapy followed by curative surgery compared with primary surgery alone for patients with resectable, nonmetastasized pancreatic adenocarcinoma (NCT01900327). The primary endpoint of the study is 3-year survival rate.
In an interview during the 2017 OncLive® State of the Science SummitTM on Gastrointestinal Cancers, Truty, an assistant professor of surgery at Mayo Clinic, discussed sequencing treatments and advances in imaging technology in pancreatic cancer. Read more . . .